📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (2020)

First Author: Yiu ZZN

Attributed to: MICA: The Newcastle Proximity Laboratory funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bjd.18981

PubMed Identifier: 32124442

Publication URI: http://europepmc.org/abstract/MED/32124442

Type: Journal Article/Review

Volume: 183

Parent Publication: The British journal of dermatology

Issue: 2

ISSN: 0007-0963